alexa The Pharmacogenetics of Nicotine Dependence and Smoking
ISSN: 2153-0645

Journal of Pharmacogenomics & Pharmacoproteomics
Open Access

Like us on:
OMICS International organises 3000+ Global Conferenceseries Events every year across USA, Europe & Asia with support from 1000 more scientific Societies and Publishes 700+ Open Access Journals which contains over 50000 eminent personalities, reputed scientists as editorial board members.

Open Access Journals gaining more Readers and Citations

700 Journals and 15,000,000 Readers Each Journal is getting 25,000+ Readers

This Readership is 10 times more when compared to other Subscription Journals (Source: Google Analytics)

Review Article

The Pharmacogenetics of Nicotine Dependence and Smoking Cessation Therapies

Martin M Zdanowicz1* and Patti W Adams2

1School of Nursing and Health Studies, University of Miami, Florida, USA

2South University School of Pharmacy, Georgia, USA

*Corresponding Author:
Martin M. Zdanowicz
School of Nursing and Health Studies
University of Miami, 5030 Brunson Drive
Coral Gables, Florida 33146
Tel: 305-284-4680
Fax: 305-284-2568
E-mail: [email protected]

Received date:July 25 2014; Accepted date: August 21, 2014; Published date: August 29, 2014

Citation: Zdanowicz MM, Adams PW (2014) The Pharmacogenetics of Nicotine Dependence and Smoking Cessation Therapies. J Pharmacogenomics Pharmacoproteomics 5:138. doi: 10.4172/2153-0645.1000138

Copyright: © 2014 Zdanowicz MM, et al. This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited

 

Abstract

Tobacco-related diseases place a tremendous burden on health-care systems world-wide. Overall mortality for smokers is nearly three-fold higher than for similar non-smokers. This increased mortality results from higher rates of cancers, vascular disease or respiratory disease. Great strides have been made in recent years with regards to understanding the neurophysiologic pathways of nicotine addiction. While a number of pharmacologic interventions have been developed to aid patients in smoking cessation, overall success rates for long-term smoking abstinence remain disappointingly low.
A growing body of evidence suggests that a number of genetic factors might influence both the severity of an individual’s nicotine addiction as well as the potential efficacy of various treatment modalities they might employ. The neurophysiology of nicotine addiction will be discussed along with genetic variants that can impact both nicotine pharmacodynamics and pharmacokinetics. The role that genetic variation plays in altering the efficacy of various smoking-cessation therapies will also be reviewed along with the potential therapeutic and economic benefits of utilizing genetic testing to optimize such drug therapies.

Keywords

Share This Page

Additional Info

Loading
Loading Please wait..
 
Peer Reviewed Journals
 
Make the best use of Scientific Research and information from our 700 + peer reviewed, Open Access Journals
International Conferences 2017-18
 
Meet Inspiring Speakers and Experts at our 3000+ Global Annual Meetings

Contact Us

 
© 2008-2017 OMICS International - Open Access Publisher. Best viewed in Mozilla Firefox | Google Chrome | Above IE 7.0 version
adwords